Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more
Briacell Therapeutics Corp (BCTX) - Total Assets
Latest total assets as of October 2025: $13.08 Million USD
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) holds total assets worth $13.08 Million USD as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Briacell Therapeutics Corp - Total Assets Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Briacell Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (July 2025)
Briacell Therapeutics Corp's total assets of $13.08 Million consist of 92.0% current assets and 8.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.5% |
| Accounts Receivable | $776.54K | 2.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $253.71K | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Briacell Therapeutics Corp's current assets represent 92.0% of total assets in 2025, an increase from 91.7% in 2006.
- Cash Position: Cash and equivalents constituted 48.5% of total assets in 2025, down from 91.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
Briacell Therapeutics Corp Competitors by Total Assets
Key competitors of Briacell Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Briacell Therapeutics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Briacell Therapeutics Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Briacell Therapeutics Corp is currently not profitable relative to its asset base.
Briacell Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.42 | 1.65 | 0.05 |
| Quick Ratio | 3.42 | 1.65 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.03 Million | $ 4.50 Million | $ -3.72 Million |
Briacell Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Briacell Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.75 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 265.1% |
| Total Assets | $29.77 Million |
| Market Capitalization | $7.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Briacell Therapeutics Corp's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Briacell Therapeutics Corp's assets grew by 265.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual total assets of Briacell Therapeutics Corp from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | $29.77 Million | +265.14% |
| 2024-07-31 | $8.15 Million | -77.53% |
| 2023-07-31 | $36.28 Million | -33.56% |
| 2022-07-31 | $54.60 Million | -24.73% |
| 2021-07-31 | $72.54 Million | +13787.95% |
| 2020-07-31 | $522.33K | +17.47% |
| 2019-07-31 | $444.66K | -80.54% |
| 2018-07-31 | $2.28 Million | +39.66% |
| 2017-07-31 | $1.64 Million | +95.78% |
| 2016-07-31 | $835.70K | -34.52% |
| 2015-07-31 | $1.28 Million | +5238.13% |
| 2014-07-31 | $23.91K | -99.75% |
| 2013-07-31 | $9.41 Million | -8.82% |
| 2012-07-31 | $10.32 Million | -16.41% |
| 2011-07-31 | $12.35 Million | +738.57% |
| 2010-07-31 | $1.47 Million | +41.73% |
| 2009-07-31 | $1.04 Million | +172.75% |
| 2008-07-31 | $380.81K | -16.54% |
| 2007-07-31 | $456.29K | +373.56% |
| 2006-07-31 | $96.35K | -- |